Copyright © 2002 by the European Society of Cardiology.
Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide
Cardiology Unit, The Queen Elizabeth Hospital, Department of Medicine, The University of Adelaide, Adelaide, SA, Australia
revised April 29, 2002; accepted May 1, 2002
Abstract
Aims To examine whether the prophylactic antianginal agent perhexiline potentiates platelet responsiveness to nitric oxide (NO) in patients with stable angina pectoris (SAP) and acute coronary syndromes (ACS: unstable angina pectoris or non-Q-wave myocardial infarction).
Methods and Results Blood samples were obtained from patients before and after initiation of treatment with perhexiline. ADP-induced platelet aggregation and its inhibition by the NO donor sodium nitroprusside (SNP) were determined via impedance aggregometry in whole blood (WB) and platelet-rich plasma (PRP). Intraplatelet cGMP content was assayed by RIA, and superoxide (O2–) level by lucigenin-derived chemiluminescence. In patients with ACS not receiving perhexiline (n=12), platelet responsiveness to SNP did not vary significantly over the first 3 days post admission to hospital. Therapy with perhexiline for 3 days was associated with increases in SNP-induced inhibition of aggregation from 29±2% to 43±4% (n=50,P <0·001) in WB and from 20±5% to 42±7% (n=12, P<0·01) in PRP. Resolution of symptomatic ischaemia (n=39) was associated with significantly greater (P<0·01) increases than non-resolution (n=11). Similar increases in SNP responsiveness (P<0·001) occurred following institution of perhexiline therapy in patients with SAP (n=30), associated with a 85% decrease in anginal frequency. Treatment with perhexiline potentiated the cGMP-elevating effects of SNP in platelets (n=9,P =0·03). Although perhexiline did not alter whole blood O2– concentration ex vivo, it inhibited (P<0·01) O2– release from neutrophils in vitro.
Conclusion Perhexiline potentiates platelet responsiveness to NO both in SAP and ACS patients; in the latter group this improvement was predictive of resolution of ischaemic symptoms. The predominant mechanism of perhexiline effect is an increase in platelet cGMP responsiveness. Perhexiline also may reduce the potential for NO clearance by neutrophil-derived O2–.
Key Words: Angina, perhexiline, nitric oxide, cGMP, platelets.
f1 Correspondence: Prof John D. Horowitz, Cardiology Unit, The Queen Elizabeth Hospital, Woodville 5011, SA, Australia.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. I. Worthley, A. S. Holmes, S. R. Willoughby, A. M. Kucia, T. Heresztyn, S. Stewart, Y. Y. Chirkov, C. J. Zeitz, and J. D. Horowitz The Deleterious Effects of Hyperglycemia on Platelet Function in Diabetic Patients With Acute Coronary Syndromes: Mediation by Superoxide Production, Resolution With Intensive Insulin Administration J. Am. Coll. Cardiol., January 23, 2007; 49(3): 304 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Willoughby, S. Stewart, A. S. Holmes, Y. Y. Chirkov, and J. D. Horowitz Platelet Nitric Oxide Responsiveness: A Novel Prognostic Marker in Acute Coronary Syndromes Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2661 - 2666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lee, J. Horowitz, and M. Frenneaux Metabolic manipulation in ischaemic heart disease, a novel approach to treatment Eur. Heart J., April 2, 2004; 25(8): 634 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Frenneaux New tricks for an old drug Eur. Heart J., December 2, 2002; 23(24): 1898 - 1899. [PDF]
|
|